EuropaBio 25th Anniversary | Healthy planet, Healthy people
At the time of the 25th Anniversary of EuropaBio, we would like to look to the future and the green transition that will shape healthcare for us all.
At the time of the 25th Anniversary of EuropaBio, we would like to look to the future and the green transition that will shape healthcare for us all.
The ‘EFIB 2021 Vienna Statement’ marked the launch of an annual call to action from EuropaBio members, with policy asks and actions critical in the short […]
The existence of messenger(m) RNA was hypothesized early in the days of DNA breakthroughs in the 1960s, and research from the 1990s started to reveal its potential as a therapeutic tool.
Managing uncertainties in rare disease innovation Joins us for the new episode of Rare Conversations 2022! The second episode of Rare Conversations 2022 will build on […]
The 2022 European Biotech Week from EuropaBio opens with a look at how biotechnology is at the centre of Europe’s transformation to a healthy, sustainable and […]
Industrial Biotechnology-derived products offer significant potential for contributing to overcoming many EU socio-economic and environmental challenges. It is not a new sector. On the contrary, for […]
Healthcare Biotechnology has the potential to transform how healthcare is delivered to patients, both in terms of innovative treatments, but also via use of innovative prevention, […]
Industrial Biotechnology for a sustainable society: a focus for 2023 and beyond Industrial biotechnology and biomanufacturing are recognised as being part of the response to some of […]
EuropaBio’s Patient BioForum meets annually to facilitate the exchange of views and expertise on scientific, regulatory, and policy issues between patient organisations and the biopharmaceutical industry. […]
EuropaBio’s first Biomanufacturing Policy Summit will set the vision for Europe’s global innovation, competitiveness and sustainability through the lens of biomanufacturing and set a baseline for […]
The development of therapies (OMPs) for rare diseases comes with distinct challenges, including patient recruitment, setting meaningful clinical endpoints, manufacturing and supply and finding the regulatory and market pathway to ensure patients can access therapy.
On 15th March, EuropaBio hosted its first Biomanufacturing Policy Summit in Brussels, with the aim of setting the vision for Europe's global innovation, competitiveness, and sustainability on biomanufacturing, while raising awareness among policy-makers.